Form 4: Amgen VP, Finance & CAO Matthew C. Busch Reports Stock Transactions

Matthew C. Busch, VP, Finance & CAO of Amgen Inc., reports the disposition and acquisition of Amgen common stock on May 2, 2025, including a sale of 1,000 shares.

Summary

• On May 2, 2025, Matthew C. Busch, VP, Finance & CAO of Amgen Inc., reported transactions involving Amgen common stock.
• Busch disposed of 28 shares and 37 shares at a price of $283.78.
• Busch sold 1,000 shares at $279.69 per share.
• Following these transactions, Busch beneficially owns 4,034 shares of Amgen common stock.
• These shares include 93 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing related to insider trading. The sentiment is neutral as it simply reports transactions without indicating positive or negative implications for the company's performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like officers and directors, trade their company's stock. These filings provide transparency into insider transactions, which can be informative but don't necessarily indicate the company's overall performance or future prospects.

Stakeholder Impact

• Shareholders may be interested in insider transactions as an indicator of management's confidence in the company.

Key Dates

Keywords

Form 4, Amgen, Stock Transaction, Beneficial Ownership, Matthew C. Busch, AMGN, Dividend Equivalents